Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2026-03-20 Audit Report / Informat…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filing from a Korean company. It provides key financial data, audit opinions, and financial statements (both consolidated and separate) for the fiscal year. While it contains financial data, it is a regulatory disclosure announcement summarizing the audit results rather than the full, multi-page annual report document itself. In the context of Korean regulatory filings (DART), this is a standard disclosure of the audit report's submission. FY 2025
2026-03-20 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement from Genome & Company. It details the final results of a third-party allocation capital increase (유상증자), including the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2026-03-13 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 95% confidence The document is a formal announcement regarding the 'Results of Securities Issuance' (증권 발행결과) for a private placement of convertible bonds (전환사채). It details the issuance amount, payment date, and the nature of the securities. This falls under capital structure changes and financing activities, which is best categorized as a Capital/Financing Update (CAP).
2026-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Genome & Company. It contains the meeting agenda, date, location, and details regarding voting procedures, including electronic voting. It also includes sections on director activities, remuneration, and business overview, which are standard components of a proxy statement or notice of meeting package provided to shareholders to solicit their votes for the upcoming AGM. This aligns with the definition of a Proxy Solicitation & Information Statement.
2026-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea for companies to solicit proxies from shareholders ahead of an Annual General Meeting (AGM). It contains details about the meeting, the agenda, and the proxy solicitation process. While it includes financial statements, these are provided as part of the meeting materials for shareholder approval, not as a standalone annual report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-03-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Genome & Company. It details the date, location, agenda items (such as financial statement approval, director appointments, and stock option grants), and specific details regarding the nominees. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2026-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.